Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®)
Titel:
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®)
Auteur:
Chiesa, C. Botta, F. Coliva, A. Maccauro, M. Devizzi, L. Guidetti, A. Carlo-Stella, C. Seregni, E. Gianni, M. A. Bombardieri, E.
Verschenen in:
European journal of nuclear medicine and molecular imaging